United States Drug Patent 6,166,043: Scope, Claims, Expiration, and Pioglitazone-Metformin Patent Landscape

U.S. Patent No. 6,166,043 protected methods for reducing the amount of antidiabetic active ingredients administered to a diabetic patient by combining an insulin-sensitivity enhancer with a biguanide. The commercial center of gravity was pioglitazone plus metformin, later marketed by Takeda as Actoplus Met.

The patent issued on December 26, 2000, and its ordinary 20-year term ran from the relevant nonprovisional or international filing date. Public patent records place the effective term end in December 2017. The patent is therefore expired and no longer creates a current U.S. barrier to generic pioglitazone-metformin products. Its historical significance was greater than its present blocking value because it covered the combination method rather than the basic pioglitazone molecule.

What does U.S. Patent 6,166,043 cover?

The patent covers a method of treating a diabetic patient with two active components:

An insulin sensitivity enhancer; and
A biguanide.

The stated therapeutic objective is reducing the amount of active components administered while maintaining a therapeutically effective treatment. The independent claim does not require a particular tablet, dose ratio, administration schedule, or fixed-dose formulation.

Claim group	Subject matter
Claim 1	Combination treatment using an insulin sensitivity enhancer and a biguanide
Claims 2-9	Structural and substituent limitations on the insulin sensitivity enhancer
Claim 10	Pioglitazone or pioglitazone hydrochloride
Claims 11-12	Biguanides, narrowed to metformin in claim 12
Claim 13	Pioglitazone or pioglitazone hydrochloride combined with metformin
Claim 14	Troglitazone combined with a biguanide
Claim 15	Rosiglitazone-type insulin sensitivity enhancer combined with a biguanide
Claim 16	The two agents mixed into an admixture
Claim 17	The two agents administered independently rather than mixed

The patent is a treatment-method patent. It is not principally a compound patent, a tablet-composition patent, or a manufacturing patent.

What is the scope of claim 1?

Claim 1 is the broadest practical claim. It requires:

A diabetic patient;
Administration of an insulin sensitivity enhancer;
Administration of a biguanide;
A therapeutically effective amount of the active components; and
A purpose or result characterized as reducing the amount of active components administered.

The claim does not limit the insulin sensitivity enhancer to pioglitazone. It reaches a broader class of compounds, subject to the claim language and the patent’s disclosure. The biguanide class includes phenformin, metformin, and buformin, although claim 11 expressly identifies those three compounds.

The main infringement issue under claim 1 would historically have been whether a product or treatment regimen administered both agents for the claimed dose-reduction purpose. A product label expressly recommending combination therapy could have been important evidence in a method-of-use case. Mere sale of a single-agent pioglitazone or metformin product would not, by itself, practice the combination claimed in claim 1.

How do claims 2 through 9 narrow the insulin sensitivity enhancer?

Claims 2 through 9 create a nested chemical genus. They narrow claim 1 through structural limitations involving:

The nature of substituent R;
Heterocyclic groups;
The values of m and n;
Whether X is carbon or nitrogen;
The linker A;
Oxygen or sulfur in the Q position;
Substitution of ring E;
The identity of R1;
The R2 substituent; and
The relationship between L and M.

The most commercially relevant narrowing sequence is:

Claim 3: R is an optionally substituted heterocyclic group.
Claim 4: m equals zero.
Claim 5: X is CH.
Claim 6: R1 is hydrogen.
Claim 7: R2 is drawn from specified substituents.
Claim 8: L and M are both hydrogen.
Claim 9: R is pyridyl, oxazolyl, or thiazolyl with specified optional substituents, with additional linker and ring restrictions.

These claims are important for claim construction and validity analysis because they move from a broad functional combination claim toward specific chemical subgenera. A defendant could challenge the broad claim while still facing separate analysis under the narrower genus claims.

Does claim 10 specifically cover pioglitazone?

Yes. Claim 10 identifies pioglitazone or its hydrochloride as the insulin sensitivity enhancer.

Pioglitazone hydrochloride is the active pharmaceutical ingredient used in Actos and in generic pioglitazone hydrochloride products. Claim 10 does not, standing alone, cover pioglitazone monotherapy. It remains dependent on claim 1 and therefore requires combination administration with a biguanide.

Claim 13 is more commercially specific because it identifies both components:

Pioglitazone or pioglitazone hydrochloride plus metformin.

Claim 13 is the clearest claim covering the Actoplus Met therapeutic concept.

Does the patent cover fixed-dose combination tablets?

Yes, but indirectly.

Claim 16 covers the situation in which the insulin sensitivity enhancer and biguanide are mixed together to form an admixture and administered to the patient. A fixed-dose tablet containing pioglitazone and metformin would fall within the factual category addressed by claim 16 if the underlying method limitations were satisfied.

The patent does not, however, claim a particular:

Tablet composition;
Excipients;
Dissolution profile;
Strength combination;
Immediate-release formulation;
Extended-release formulation;
Manufacturing process; or
Packaging configuration.

A later formulation patent could have provided a separate layer of protection even after the 6,166,043 method patent expired.

Does claim 17 cover separate administration?

Yes. Claim 17 expressly covers administration in which the two active ingredients are not mixed together but are administered independently.

This language materially broadens the practical reach of the patent. The claimed method could be practiced through:

A combination tablet;
Two separate tablets taken together;
Separate prescriptions used in the same regimen; or
Sequential administration, depending on the facts and the meaning of administration under the patent and applicable case law.

The patent therefore was not limited to Actoplus Met or another fixed-dose product.

Which drugs are included in the patent’s insulin-sensitivity enhancer class?

The claims expressly identify or structurally encompass several thiazolidinedione-related agents.

Insulin sensitivity enhancer	Treatment status	Relevance to U.S. Patent 6,166,043
Pioglitazone	FDA-approved	Expressly identified in claim 10
Pioglitazone hydrochloride	FDA-approved salt form	Expressly identified in claim 10
Troglitazone	Withdrawn from the U.S. market	Expressly identified in claim 14
Rosiglitazone-type compound	FDA-approved historically as Avandia	Identified by the chemical name in claim 15
Other claimed structural analogues	Depends on identity and claim construction	Covered only if within the relevant structural genus

The patent does not establish current regulatory approval for every compound within its chemical formula. Patent coverage and FDA approval are separate inquiries.

When did U.S. Patent 6,166,043 lose exclusivity?

The patent’s effective U.S. term ended in December 2017. The patent was issued on December 26, 2000, but the term is generally measured from the applicable filing date rather than the issue date under the Uruguay Round Agreements Act framework.

Event	Date or period
Earliest priority period	December 1996, based on the disclosed Japanese priority history
U.S. or international filing period	December 1997
U.S. patent grant	December 26, 2000
Expected ordinary term end	December 2017
Current status	Expired
Current blocking effect	None in the United States

The expiration date should be distinguished from any possible patent-term adjustment, terminal disclaimer, patent-term extension, or correction recorded in the official USPTO file. The patent did not receive a meaningful commercial life extension comparable to a five-year Hatch-Waxman patent-term extension.

What was the Orange Book status of U.S. Patent 6,166,043?

The patent was relevant to the Actoplus Met product and to the historical patent protection for pioglitazone-metformin combination therapy. The FDA Orange Book is the principal source for determining whether a patent was submitted for an approved drug and whether it was listed against a specific NDA.

The Orange Book distinction is important:

A patent can be listed against a drug product without covering the active ingredient itself.
A method-of-use patent can be listed when it claims an approved use.
A formulation or drug-product patent can be listed separately from a compound patent.
Expiration removes the patent as a current Orange Book barrier, even if the historical listing remains relevant to the product’s regulatory history.

For current generic entry analysis, U.S. Patent 6,166,043 is an expired patent. It cannot support a new Paragraph IV enforcement action or delay approval of an ANDA today. Historical ANDA applicants could have addressed it through a Paragraph IV certification, a section viii statement where appropriate, or a certification based on expiration, depending on the timing and listing status.

Were Paragraph IV challenges relevant to this patent?

Yes, historically. A generic applicant seeking approval for a pioglitazone-metformin product would have evaluated the patent if it was listed against the relevant reference product and if the proposed labeling implicated the claimed method.

A Paragraph IV certification would assert that the patent was invalid, unenforceable, or would not be infringed. Potential arguments included:

Lack of novelty;
Obviousness of combining a thiazolidinedione with metformin;
Lack of adequate written description for the broad chemical genus;
Lack of enablement across the full breadth of the Markush formula;
Failure to prove the claimed reduction in administered active amounts;
Noninfringement based on labeling, dosing, or patient-selection limitations; and
Improper or incomplete Orange Book listing.

The most commercially significant claim would have been claim 13, because it maps directly onto pioglitazone plus metformin. Claim 1 would have presented the broadest scope but also the greatest potential validity and construction issues.

What patent litigation affected pioglitazone and Actoplus Met?

The major U.S. patent disputes surrounding pioglitazone involved Takeda’s core pioglitazone patents and later generic challenges to Actos. Those disputes included ANDA litigation against several generic manufacturers and addressed the validity, enforceability, and scope of Takeda’s pioglitazone patent estate.

The litigation environment included generic applicants such as:

Mylan;
Teva;
Ranbaxy;
Watson or Actavis; and
Other ANDA sponsors.

The central commercial disputes focused on whether generic products could launch before expiration of the core Actos patents and whether Takeda’s patents were valid and enforceable. U.S. Patent 6,166,043 was a combination-treatment patent within that broader estate. It was narrower than the principal compound and basic-use patents because it required co-administration with a biguanide.

After the patent expired in 2017, it ceased to provide a viable basis for an injunction against a U.S. generic product. Any historical settlement terms would need to be assessed from the relevant litigation docket and agreement because the expiration date alone does not establish the contents of a settlement.

How strong was the patent estate for pioglitazone-metformin therapy?

The estate had moderate historical strength but limited current strength.

Strengths

Claim 13 directly identified pioglitazone and metformin.
Claim 17 reached separate administration, reducing dependence on a fixed-dose tablet.
Claim 16 addressed a mixed admixture and therefore supported a fixed-dose combination theory.
The patent’s claim structure covered both broad combination treatment and narrower chemical embodiments.
The claims were aligned with an approved therapeutic practice for type 2 diabetes.

Weaknesses

The underlying pioglitazone molecule was protected by separate earlier patents, not by this patent.
The broad combination concept could face obviousness arguments based on known use of metformin and insulin-sensitizing agents.
Claim 1 contains a functional dose-reduction concept that could create proof issues.
The patent does not claim a particular dose, ratio, formulation, or pharmacokinetic profile.
The patent term expired before current commercial disputes over many newer combination formulations arose.

The strongest historical claim was likely claim 13 for a pioglitazone-metformin treatment regimen. The strongest product-facing claim was claim 16 when the product contained both agents in one dosage form. Claim 17 was broader from a regimen perspective but could be more dependent on proof of the claimed therapeutic purpose.

What formulations were protected after the combination patent expired?

The expiration of U.S. Patent 6,166,043 did not automatically eliminate every possible patent issue for pioglitazone-metformin products. Separate patents could address:

Extended-release metformin;
Bilayer or multilayer tablets;
Specific pioglitazone-to-metformin ratios;
Controlled release;
Multiparticulate systems;
Stability improvements;
Dissolution characteristics;
Manufacturing processes; and
Treatment methods involving particular patient populations.

Those rights must be analyzed by patent number and claim scope. They are distinct from the expired combination-method claims in U.S. Patent 6,166,043.

Is there biosimilar risk for pioglitazone or Actoplus Met?

No biosimilar pathway applies.

Pioglitazone and metformin are chemically synthesized small molecules. Follow-on products are approved through the ANDA pathway under section 505(j) of the Federal Food, Drug, and Cosmetic Act, not through the abbreviated biologics license application pathway under the Public Health Service Act.

The relevant competitive risks are:

Generic pioglitazone hydrochloride;
Generic metformin;
Generic fixed-dose pioglitazone-metformin tablets;
Authorized generics; and
Therapeutic substitution by other type 2 diabetes products.

What manufacturing and geographic barriers remain?

The patent’s manufacturing barrier is limited. U.S. Patent 6,166,043 does not claim a synthesis route, crystal form, impurity profile, or manufacturing process. Once the patent expired, it left no independent U.S. process barrier.

Geographic coverage was jurisdiction-specific. The U.S. patent could affect conduct involving U.S. treatment, U.S. product sales, or U.S. labeling, but it did not automatically control:

European sales;
Japanese sales;
Canadian sales;
Manufacturing entirely outside the United States; or
Foreign treatment methods.

Foreign family members required separate validity and expiration analysis. Patent expiration in the United States did not establish the status of corresponding patents in Europe, Japan, or other jurisdictions.

What generic launch scenarios existed?

Before expiration, generic launch outcomes could be divided into four scenarios:

Scenario	Commercial result
Patent upheld and infringed	Launch delayed until expiration or settlement date
Patent invalidated	Earlier launch possible
Noninfringement established	Product could launch despite the patent
Settlement reached	Launch governed by the settlement’s authorized-entry date

After December 2017, the patent no longer supported a delayed U.S. launch. Generic applicants could compete on the basis of FDA approval, remaining Orange Book patents, product availability, manufacturing capacity, and commercial contracting.

How does U.S. Patent 6,166,043 compare with core Actos patents?

Issue	U.S. Patent 6,166,043	Core Actos patent estate
Primary subject	Combination therapy	Pioglitazone compound and basic therapeutic use
Key product	Actoplus Met concept	Actos and generic pioglitazone
Main active ingredients	Insulin sensitivity enhancer plus biguanide	Pioglitazone
Fixed-dose coverage	Indirectly through claim 16	Generally not the central subject
Separate administration	Expressly covered by claim 17	Not the central subject
Current status	Expired	Core rights also expired or otherwise no longer block ordinary generic entry
Commercial importance	Combination-product protection	Foundational protection for the pioglitazone franchise

The distinction matters in freedom-to-operate work. A company could avoid this patent by selling pioglitazone alone, but it could still encounter separate patent issues for the active ingredient, formulation, or a different approved use during the relevant historical period.

What is the current commercial exposure?

Current revenue exposure from U.S. Patent 6,166,043 is zero as a live exclusivity right. The patent cannot prevent U.S. generic competition or create a new statutory approval stay.

The commercial effects of expiration include:

No enforceable U.S. exclusivity for pioglitazone-metformin combination treatment;
No current Paragraph IV settlement leverage based on this patent;
No current Orange Book blocking period based on this patent;
Reduced value of the branded Actoplus Met combination; and
Greater importance for generic manufacturers of supply, pricing, reimbursement, and contracting strategy.

Takeda’s historical revenue exposure was tied more heavily to the overall Actos franchise than to this single combination patent. The patent supported lifecycle management by protecting combination use and the fixed-dose product concept after the core pioglitazone franchise matured.

Key Takeaways

U.S. Patent 6,166,043 covered combination treatment of diabetes with an insulin sensitivity enhancer and a biguanide.
Claim 13 specifically covered pioglitazone or pioglitazone hydrochloride with metformin.
Claim 16 addressed mixed combination products, while claim 17 covered separate administration.
The patent was a method-of-use patent, not a basic pioglitazone compound patent.
Its U.S. term ended in December 2017.
It is expired and has no current U.S. blocking effect.
Historical Paragraph IV issues would have centered on obviousness, enablement, claim construction, and whether generic labeling practiced the claimed method.
Pioglitazone and metformin are small molecules, so generic competition proceeds through ANDA filings rather than biosimilar applications.
Remaining risks must be evaluated against separate formulation, process, crystal-form, and method-of-use patents.

FAQs

Does U.S. Patent 6,166,043 cover pioglitazone monotherapy?

No. The claims require administration of an insulin sensitivity enhancer together with a biguanide. Pioglitazone alone does not satisfy the combination limitation.

Does the patent cover Actoplus Met?

Historically, yes. Claim 13 directly identifies pioglitazone plus metformin, and claim 16 addresses the mixed-admixture form associated with a fixed-dose combination product.

Could a generic company launch pioglitazone-metformin before 2017?

Only after resolving the patent through expiration, invalidity, noninfringement, a successful Paragraph IV position, or a settlement permitting earlier entry. The patent expired in December 2017.

Is claim 17 limited to patients taking the two drugs at the same time?

No express simultaneous-administration requirement appears in claim 17. The claim distinguishes mixed administration from independent administration, but the precise timing and factual scope would depend on claim construction and the patent’s disclosure.

Does expiration of this patent eliminate all patent risk for pioglitazone-metformin products?

No. Separate patents may cover formulations, release profiles, manufacturing processes, solid forms, or other treatment methods. Each must be evaluated independently.

References

U.S. Patent No. 6,166,043. (2000). Treatment of diabetes using an insulin sensitivity enhancer and a biguanide. United States Patent and Trademark Office.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations (Orange Book). U.S. Department of Health and Human Services.
U.S. Food and Drug Administration. (2005). Actoplus Met: Prescribing information. U.S. Department of Health and Human Services.
U.S. Food and Drug Administration. (2023). Drugs@FDA: FDA-approved drugs. U.S. Department of Health and Human Services.
United States Code, 35 U.S.C. §§ 154, 271, and 282.
Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0861666	⤷ Start Trial	91298	Luxembourg	⤷ Start Trial
European Patent Office	0861666	⤷ Start Trial	300258	Netherlands	⤷ Start Trial
European Patent Office	0861666	⤷ Start Trial	SPC 038/2006	Ireland	⤷ Start Trial
European Patent Office	0861666	⤷ Start Trial	07C0006	France	⤷ Start Trial
European Patent Office	0861666	⤷ Start Trial	CA 2007 00001	Denmark	⤷ Start Trial
European Patent Office	0861666	⤷ Start Trial	SPC/GB07/009	United Kingdom	⤷ Start Trial
European Patent Office	0861666	⤷ Start Trial	C00861666/01	Switzerland	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,166,043

Summary for Patent: 6,166,043